Answers are grounded in this paper and cite their sources.
Biomarkers reflect underlying physiological or pathological processes and support disease detection, cancer diagnosis, treatment selection and prognosis, monitoring of therapeutic response, and identification of disease recurrence in interventional oncology (IO) care. In recent years, liquid biopsy of circulating biomarkers has emerged as a transformative approach in oncology. Given the growing role of IO in cancer care and the potential for circulating biomarkers to directly impact patient care in Interventional Radiology, this narrative review summarizes circulating biomarker types, current detection technologies and workflows, clinical applications in IO care, and next-generation biomarker modalities and detection instruments for Interventional Radiologists.
No takes yet. Share an insight, caveat, or question.
Gaba et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: